How Short Is Safe? Duration of Dual Antiplatelet Therapy Before Aspirin Withdrawal After Percutaneous Coronary Intervention: A Dose-Response Network Meta-Analysis
- 1Dongguk University Ilsan Hospital
Abstract
Background: Trials of P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI) withdrew aspirin at fixed times, mostly against 12-month dual antiplatelet therapy (DAPT), and categorical syntheses disagree. Methods: Bayesian model-based network meta-analysis of randomized trials of aspirin withdrawal with P2Y12 inhibitor continuation, with 12-month myocardial infarction (MI) and major bleeding modeled as functions of DAPT duration (Emax and spline). The prespecified estimand was the shortest duration at which the upper 95% credible limit of the odds ratio (OR) for MI versus 12-month DAPT fell below 1.15. Results: Sixteen trials (17 randomized comparisons, 58,068 patients) contributed 929 MIs and 1,102 major bleeding events. The OR for MI was 1.31 (95% credible interval 0.95-2.09) at 0 days, 1.17 (0.96-1.43) at 30 days, and 1.09 (0.98-1.25) at 90 days. Under every model the point estimate exceeded 1.15 below about 3 weeks and fell below it from about 90 days; a 30-day change-point did not fit better. The credible bound was met at 158 days (Emax) and 282 days (spline). Bleeding decreased with shorter duration (OR 0.40 at 0 days, 0.62 at 90 days). Certainty was low for MI below 90 days and the estimand, moderate for bleeding. Conclusions: Shorter DAPT reduced major bleeding, and the ischemic cost of aspirin withdrawal declined with duration; a step at 1 month was not supported. A 15% excess of MI could be excluded from about 5 months (Emax) or 9 months (spline). The curves match duration to each patient's ischemic margin.
Related
- Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials
- Antiplatelet Therapy Strategies in Patients with High Bleeding Risk Treated with Complex Percutaneous Coronary Intervention: A Descriptive Study
- Spontaneous Spinal Epidural Hematoma: An Urgent Complication of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Non-ST-elevation Myocardial Infarction
- Antiplatelet monotherapy maintenance strategies after percutaneous coronary intervention in patients with coronary artery disease at high bleeding risk: a network meta-analysis
- High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention: How to Choose the Optimal Antithrombotic Therapy, Its Duration and the Right Stent; A Comprehensive Review of the Current Literature and Proposed Treatment Algorithms
BibTeX
@misc{jang2026short,
title = {{How Short Is Safe? Duration of Dual Antiplatelet Therapy Before Aspirin Withdrawal After Percutaneous Coronary Intervention: A Dose-Response Network Meta-Analysis}},
author = {J.-S. Jang and K.-H. Kim and J. S. Park and E.-M. Lee and M.-Y. Rhee},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.28.26366775},
url = {https://www.medrxiv.org/content/10.64898/2026.10.28.26366775v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - How Short Is Safe? Duration of Dual Antiplatelet Therapy Before Aspirin Withdrawal After Percutaneous Coronary Intervention: A Dose-Response Network Meta-Analysis
AU - J.-S. Jang
AU - K.-H. Kim
AU - J. S. Park
AU - E.-M. Lee
AU - M.-Y. Rhee
PY - 2026
DA - 2026/10/28
PB - medRxiv
DO - 10.64898/2026.10.28.26366775
UR - https://www.medrxiv.org/content/10.64898/2026.10.28.26366775v1
AB - Background: Trials of P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI) withdrew aspirin at fixed times, mostly against 12-month dual antiplatelet therapy (DAPT), and categorical syntheses disagree. Methods: Bayesian model-based network meta-analysis of randomized trials of aspirin withdrawal with P2Y12 inhibitor continuation, with 12-month myocardial infarction (MI) and major bleeding modeled as functions of DAPT duration (Emax and spline). The prespecified estimand was the shortest duration at which the upper 95% credible limit of the odds ratio (OR) for MI versus 12-month DAPT fell below 1.15. Results: Sixteen trials (17 randomized comparisons, 58,068 patients) contributed 929 MIs and 1,102 major bleeding events. The OR for MI was 1.31 (95% credible interval 0.95-2.09) at 0 days, 1.17 (0.96-1.43) at 30 days, and 1.09 (0.98-1.25) at 90 days. Under every model the point estimate exceeded 1.15 below about 3 weeks and fell below it from about 90 days; a 30-day change-point did not fit better. The credible bound was met at 158 days (Emax) and 282 days (spline). Bleeding decreased with shorter duration (OR 0.40 at 0 days, 0.62 at 90 days). Certainty was low for MI below 90 days and the estimand, moderate for bleeding. Conclusions: Shorter DAPT reduced major bleeding, and the ischemic cost of aspirin withdrawal declined with duration; a step at 1 month was not supported. A 15% excess of MI could be excluded from about 5 months (Emax) or 9 months (spline). The curves match duration to each patient's ischemic margin.
ER -